Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00534495 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults
A Phase 2 study, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 71
- Enrollment target
NCT00534495 is a Phase 2 study that has completed, run by Montefiore Medical Center. The registered enrollment target is 71 participants.
The verdict
NCT00534495, a Phase 2 study, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 71 participants
- Enrollment target
Study Summary
Systemic juvenile idiopathic arthritis (SJIA) is a type of arthritis that typically occurs before 16 years of age. SJIA usually involves heat, pain, swelling, and stiffness in the body's joints. It can also involve fever, rash, anemia, and inflammation in various parts of the body. Rilonacept is a drug that can reduce inflammation. The purpose of this study is to determine whether a rilonacept drug regimen initiated early is more effective than a similar rilonacept drug regimen initiated 4 weeks later when treating children and young adults with SJIA.
Interventions
- BIOLOGICAL Rilonacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2008-11 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00534495
The ClinicalTrials.gov registry entry for NCT00534495 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rilonacept is the first listed.
NCT00534495 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00534495 about?
NCT00534495 is a clinical study titled "Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults". Systemic juvenile idiopathic arthritis (SJIA) is a type of arthritis that typically occurs before 16 years of age. SJIA usually involves heat, pain, swelling, and stiffness in the body's joints. It can also involve fever, rash, anemia, and inflammation in various parts of the body. Rilonacept is a d...
What is the current status of trial NCT00534495?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2008-11. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00534495?
The interventions under investigation include: Rilonacept (BIOLOGICAL).
Who is sponsoring clinical trial NCT00534495?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.